Finding Funding in Biotechnology: Keeping the Companies Alive

Mark D. Dibner;Michael Howell;

Publication

Article

June 15, 2002

BioPharm International

BioPharm International-06-01-2002

Volume15

Issue 6

Finding Funding in Biotechnology: Keeping the Companies Alive

Author(s):

Mark D. Dibner,Michael Howell

by Mark D. Dibner, BioAbility, LLC, and Michael Howell Biotechnology appears to be "the place to be" for venture capitalists, capturing the largest percentage increase in investment for 2001. The value of biotech companies has risen sharply, and many economists are predicing an end to the IPO drought.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

Negotiating and Structuring Strategic Alliances

Finding Funding in Biotechnology: Keeping the Companies Alive

Biotechnology Patent Holders Beware! A Supreme Court Ruling may Significantly Reduce the Value of Your Patent Portfolio

Guest Editorial: Enabling Collaboration in the Pharmaceutical Industry

Stem Cells and Xenotransplantation: Ethics, Patents, and Politics

Unlocking the Value of R&D: Managing the Risks

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Finding Funding in Biotechnology: Keeping the Companies Alive

Newsletter